Tobramycin: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(33 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
{{Details0|Tobramycin (inhalation)}}
{{Tobramycin}}
{{Details0|Tobramycin (Injection)}}
{{CMG}}
{{Details0|Tobramycin (opthalmic)}}
 
==Overview==
 
'''Tobramycin''' is an [[aminoglycoside]] [[antibiotic]] derived from [[Streptomyces tenebrarius]] and used to treat various types of [[bacteria]] infections, particularly [[Gram-negative]] infections. It is especially effective against species of [[Pseudomonas]].<ref>{{ cite web | title = Tobramycin | url = http://www.toku-e.com/Upload/Products/PDS/20120515001224.pdf | format = pdf | publisher = Toku-E | date = 2010-01-12 | accessdate = 2012-06-11 }}</ref>
 
==Category==
 
Aminoglycoside
 
==US Brand Names==
 
AKTOB, BETHKIS, NEBCIN, TOBI, TOBRAMYCIN, TOBREX, ZYLET
 
==FDA Package Insert==
 
'''  [[Tobramycin description|Description]]'''
'''| [[Tobramycin clinical pharmacology|Clinical Pharmacology]]'''
'''| [[Tobramycin microbiology|Microbiology]]'''
'''| [[Tobramycin indications and usage|Indications and Usage]]'''
'''| [[Tobramycin contraindications|Contraindications]]'''
'''| [[Tobramycin warnings and precautions|Warnings and Precautions]]'''
'''| [[Tobramycin adverse reactions|Adverse Reactions]]'''
'''| [[Tobramycin drug interactions|Drug Interactions]]'''
'''| [[Tobramycin overdosage|Overdosage]]'''
'''| [[Tobramycin clinical studies|Clinical Studies]]'''
'''| [[Tobramycin dosage and administration|Dosage and Administration]]'''
'''| [[Tobramycin how supplied|How Supplied]]'''
'''| [[Tobramycin labels and packages|Labels and Packages]]'''
 
==Mechanism of Action==
 
 
 
'''Tobramycin sulfate''' is an [[aminoglycoside]] [[antibiotic]] used to treat various types of [[bacterium|bacteria]]l infections, particularly [[Gram-negative]] infections.
 
==Mechanism of action==
Tobramycin works by binding to a site on the bacterial [[30S]] and [[50S]] [[ribosome]], preventing formation of the 70S complex.  As a result, [[mRNA]] cannot be [[Translation (biology)|translated]] into protein and cell death ensues.
 
==Administration==
Like all aminoglycosides, tobramycin does not pass the [[gastro-intestinal tract]], so for [[systemic]] use it can only be given [[Intravenous therapy|intravenously]] or [[Intramuscular injection|intramuscularly]]. This formulation for injection is branded Nebcin®. Patients with [[cystic fibrosis]] will often take an [[inhaler|inhalational]] form (Tobi®) for suppression of ''[[Pseudomonas aeruginosa]]'' infections. Tobramycin is also combined with [[dexamethasone]] as an [[TobraDex|ophthalmic solution]] (TobraDex®).
 
Bausch & Lomb Pharmaceuticals, Inc. makes a sterile Tobramycin [[Ophthalmology|Ophthalmic]] Solution (eye-drops) with a tobramycin concentration of 0.3%, which is available by prescription only in the United States and Canada. (In some countries, such as Italy, it is available over the counter.)  It is mixed with 0.01% [[benzalkonium chloride]] as a preservative.  These concentrations result in 3 mg per ml and 0.1 mg per ml, respectively.
 
==Side effects==
Like other aminoglycosides, tobramycin can cause [[deafness]] or a loss of [[equilibrioception]] (vertigo) in genetically susceptible individuals. These individuals have a normally harmless mutation in their DNA, that allows the tobramycin to affect their cells. The cells of the [[ear]] are particularly sensitive to this.
 
Tobramycin can also be highly [[nephrotoxic|toxic]] to the [[kidney]]s, particularly if multiple doses accumulate over a course of treatment.
 
For these reasons, when tobramycin is given [[parenteral]]ly, it is usually dosed by [[body weight]]. Various formulae exist for calculating tobramycin dosage. Also serum levels of tobramycin are monitored during treatment.
 
 
==References==
{{Reflist|2}}
 
[[Category:Antibiotics]]
[[Category:Wikinfect]]

Latest revision as of 19:19, 6 May 2015